MeDucation· @MeDucationai · X·· 4 天前评分70
正文 · 机器翻译
@ChandrakanthMv 的七点拆解让 FOURLIGHT-1 易于教学。对 fellow 们而言，其中的微妙之处在于：atirmociclib 是 CDK4 选择性的，保留 CDK6 旨在缓解中性粒细胞减少症这一制约当前 CDK4/6 抑制剂的因素。#ESMO26 #BCSM
56 浏览 · 1 赞 · 0 转发 · 0 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.orgFOURLIGHT-1 | ESMO 2026 Can CDK4 inhibition work after CDK4/6 progression? 1. Population: 263 patients with HR+/HER2− advanced breast cancer after prior CDK4/6 inhibitor. 2. Arms: Atirmociclib + fulvestrant vs investigator’s choice (fulvestrant or everolimus + exemestane). 3. Median PFS: 9.4 vs 6.6 months (HR 0.60). 4. ORR: 19.3% vs 11.3%. 5. Clinical benefit ≥24 weeks: 61.9% vs 46.0%. 6. Safety: Neutropenia 46.4%; leukopenia 32.8%; treatment-related discontinuation 4%. 7. Take-home: Promising phase II PFS benefit. OS immature; phase III confirmation needed. Ref: Giordano A, et al. FOURLIGHT-1. ESMO 2026; Abstract 1842O. #ESMO26 #BreastCancer #MVOnco在 X 查看被引用的帖子
来源：MeDucation · x.com